OPKO completes sale of BioReference oncology assets to Labcorp for $192.5M cash plus earnout

OPKO HEALTH, INC.

Transaction closed Sept 15, 2025; Labcorp paid $192.5M at closing, with up to $32.5M earnout.
Assets include BioReference's oncology and oncology-related clinical testing services across the U.S.
OPKO to use portion of proceeds for share repurchase; continuing ops had ~$300M revenue in 2024.
CEO Phillip Frost says deal positions BioReference to focus on core testing and 4Kscore franchise.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.